| Code | CSB-RA010327MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ficlatuzumab, targeting hepatocyte growth factor (HGF). HGF is a pleiotropic cytokine that binds to the MET receptor tyrosine kinase, initiating signaling cascades that regulate cell proliferation, survival, migration, and morphogenesis. The HGF/MET pathway plays crucial roles in embryonic development, tissue regeneration, and wound healing. Aberrant activation of this pathway is implicated in tumor growth, metastasis, and therapeutic resistance across multiple cancer types, including non-small cell lung cancer, gastric cancer, and renal cell carcinoma, making it an important target for oncology research.
Ficlatuzumab is a humanized IgG1 monoclonal antibody that inhibits HGF binding to the MET receptor, thereby blocking downstream oncogenic signaling. This biosimilar antibody serves as a valuable research tool for investigating HGF-mediated mechanisms in cancer biology, tumor microenvironment interactions, and resistance to targeted therapies. It enables researchers to explore the therapeutic potential of HGF inhibition in preclinical models and to elucidate the molecular mechanisms underlying MET pathway activation in disease contexts.
There are currently no reviews for this product.